ArticleCornea2017
Kinetics of Angiogenic Responses in Corneal Transplantation.
Article in Cornea, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Role of PD-L1 in Regulatory T Cell-Mediated Suppression of Corneal Neovascularization.The American journal of pathology · 2025Article
- Advances in 3D Bioprinting for Corneal Regeneration.Gels (Basel, Switzerland) · 2025Review
- Preserved bevacizumab (Avastin®) eye drops for application in multidose containers - an in-vitro characterisation.BMC veterinary research · 2025Article
- Toll-like receptor 2 deficiency exacerbates corneal angiogenesis in injury by impairing regulatory T cells.Theranostics · 2025Article
- Myeloid-derived suppressor cells promote allograft survival by suppressing regulatory T cell dysfunction in high-risk corneal transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Review
- Local and Systemic Injections of Human Cord Blood Myeloid-Derived Suppressor Cells to Prevent Graft Rejection in Corneal Transplantation.Biomedicines · 2022Article
- Promotion of corneal angiogenesis by sensory neuron-derived calcitonin gene-related peptide.Experimental eye research · 2022Article
- Changing Medical Paradigm on Inflammatory Eye Disease: Technology and Its Implications for P4 Medicine.Journal of clinical medicine · 2022Article
- Anti-CD80/86 antibodies inhibit inflammatory reaction and improve graft survival in a high-risk murine corneal transplantation rejection model.Scientific reports · 2022Article
- Piperlongumine alleviates corneal allograft rejectionFrontiers in immunology · 2022Article
- Role of Immune Cell Diversity and Heterogeneity in Corneal Graft Survival: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2021Review
- Loss of miR-673-5p expression in the cornea promotes rat corneal allograft rejection by promoting Th17 cell differentiation mediated by JAK2/STAT3.Annals of translational medicine · 2021Article
- Ex Vivo-Induced Bone Marrow-Derived Myeloid Suppressor Cells Prevent Corneal Allograft Rejection in Mice.Investigative ophthalmology & visual science · 2021Article
- Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation.Scientific reports · 2021Article
- Corneal angiogenic privilege and its failure.Experimental eye research · 2021Review
- Novel adaptation of a running suture technique in a mouse model of corneal transplantation.Journal of biological methods · 2021Article
- Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection.Frontiers in immunology · 2021Article
- Novel immunotherapeutic effects of topically administered ripasudil (K-115) on corneal allograft survival.Scientific reports · 2020Article
- Sensory neurons directly promote angiogenesis in response to inflammation via substance P signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo delineate and compare the kinetics of corneal angiogenesis after high-risk (HR) versus low-risk (LR) corneal transplantation.
methodsIn mice, intrastromal sutures were placed in the recipient graft bed 2 weeks before allogeneic transplantation to induce angiogenesis and amplify the risk of graft rejection. Control (LR) graft recipients did not undergo suture placement, and thus the host bed remained avascular at the time of transplantation. Graft hemangiogenesis and opacity scores were evaluated for 8 weeks by slit-lamp biomicroscopy. Immunohistochemistry was used to measure CD31 (blood vessels) and LYVE-1 (lymphatic vessels) cells.
resultsBiphasic kinetics were observed for hemangiogenesis in both HR and LR transplant recipients using clinical and immunohistochemical assessments. The biphasic kinetics were composed of a rise-fall (phase 1) followed by a second rise (phase 2) in the degree of vessels. Compared with LR recipients, HR recipients showed higher hemangiogenesis (whole cornea and graft) throughout 8 weeks. Analyzing grafts revealed sustained presence of lymphatic vessels in HR recipients; however, lymphatic neovessels regressed in LR recipients 2 weeks posttransplantation. In contrast to HR host beds, the LR host bed microenvironment cannot sustain the growth of lymphatic neovessels in allografts, whereas it can sustain continued hemangiogenesis.
conclusionsThe sustained presence of lymphatic vessels in HR host beds can facilitate host immunity against allografts and is likely associated with ongoing higher risk of rejection of these grafts in the long term, suggesting that therapeutic interventions targeting inflammation and lymphatic vessels need to be sustained long term in the HR corneal transplant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.